英文名称: AMG 232; KRT-232 总访问: 147 国产/进口: 进口 半年访问: 1 产地/品牌: MedChemExpress(MCE) 产品类别: 生化试剂 规格: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg 最后更新: 2024-11-4 货号: HY-12296 CAS 号: 1352066-68-2 参考报价: 1800; 2800; 6000; 10500; 16500 立即询价 ...
Navtemadlin is a potent, selective, orally available MDM2 inhibitor that overcomes MDM2 dysregulation by restoring p53 activity and inducing apoptosis ofTP53WTtumors.Methods:The dose-finding, phase 1b/2 KRT-232-103 study (NCT03787602) evaluated navtemadlin in adultTP53WTMCC pts who failed anti-...
Together, these studies provide biological and clinical support for evaluating navtemadlin in patients with R/R AML secondary to MPN.Methods:The open-label, multicenter Phase 1b/2 KRT-232-104 study (NCT04113616) is evaluatingTP53WTpatients with R/R AML secondary to MPN (myelofibrosis, ...
英文名称: AMG 232-d7; KRT-232-d7 总访问: 69 国产/进口: 进口 半年访问: 2 产地/品牌: MedChemExpress(MCE) 产品类别: 生化试剂 规格: 电询 最后更新: 2024-11-4 货号: HY-12296S CAS 号: 参考报价: 电询 立即询价 电话咨询 [发表评论] [本类其他产品] [本类其他供应商] [收藏] 分享...
KRT-232–118 is a Global 2-part Phase 2/3 study evaluating the safety and efficacy of navtemadlin maintenance therapy in TP53WT advanced/recurrent EC patients following response to chemotherapy (EudraCT 2022–5002196-31; NCT05797831). Methods Adults with ECOG PS 0–1 who completed up to 6 ...
Results NA Study schema of KRT-232–118 Conclusion NA Disclosures Funded by Kartos Therapeutics Inc.Nicole ConcinUgo De GiorgiToon Van GorpJérme AlexandreKristina LindemannChristian MarthRegina BergerDavid CibulaMaría QuindósAlessandra BolognaInternational Journal of Gynecological Cancer...
NRG-DT001 phase Ib trial of neoadjuvant navtemadlin (previously AMG232 and KRT232) concurrent with preoperative radiotherapy in wild-type p53 soft tissue sarcoma of the extremity and body wall.doi:10.1200/JCO.2022.40.16_suppl.1152153111521#Background:NRG-DT001 is a phase Ib trial evaluating...
Navtemadlin (KRT-232) is a potent, selective, orally available MDM2 inhibitor that restores p53 function to drive apoptosis ofTP53WTmalignancies. Treatment with navtemadlin may be an effective strategy for patients withTP53WTSCLC.Methods:The open-label, multicenter Phase 2 KRT-232-112 study (...
关键字: MDM-2/p53 | inhibit | Ubiquitin ligase | Ubiquitin activating enzyme | E3 ligating enzyme | E2 conjugating enzyme | E1/E2/E3 Enzyme | AMG 232 | Ubiquitin conjugating enzyme | AMG-232 | KRT232 | KRT 232 | KRT-232 | CS1300 | E1 activating enzyme | Navtemadlin | CS 1300 |...